Economy/Home · Economy

Hanmi Pharm Jumps 6.43%, Breaking Above 370,000 Won... iM Securities Maintains 600,000 Won Target Price; Epeleglenatide's 'Price Competitiveness' Key to Commercialization

Hanmi Pharmaceutical (128940) showed strong upward momentum, surpassing the 370,000-won level. As the commercialization potential of its obesity treatment candidate epeleglenatide draws attention, brokerages analyze that alongside clinical competitiveness, the actual selling price will be a key vari

Wooil Shim
Staff Reporter
6 min read
Hanmi Pharm Jumps 6.43%, Breaking Above 370,000 Won... iM Securities Maintains 600,000 Won Target Price; Epeleglenatide's 'Price Competitiveness' Key to Commercialization
CBC News

Hanmi Pharmaceutical (128940) showed strong upward momentum, surpassing the 370,000-won level. As the commercialization potential of its obesity treatment candidate epeleglenatide draws attention, brokerages analyze that alongside clinical competitiveness, the actual selling price will be a key variable for market positioning.

On the 28th, Hanmi Pharmaceutical was trading at 373,000 won, up 22,550 won from the previous trading day, a gain of about 6.43%. With the stock price rising to the 370,000-won range, interest in the company's obesity drug development achievements and future commercialization strategy is also growing.

■ iM Securities Maintains 'Buy' Rating and 600,000 Won Target Price

iM Securities maintained its 'Buy' investment opinion and 600,000-won target price for Hanmi Pharmaceutical. Based on the closing price of 350,500 won on the 27th, the upside potential to the target price reached about 71.2%. However, recalculated based on the 28th's trading price of 373,000 won, the upside narrows to about 60.9%.

Researcher Jung Jae-won of iM Securities assessed that the actual selling price will be as decisive a factor for future market positioning as epeleglenatide's clinical competitiveness.

■ Obesity Drug Market: 'Price Structure' to Determine Prescription Expansion

The obesity treatment market is a sector where not only efficacy and safety but also a cost structure that allows patients to sustain long-term treatment are important. In particular, obesity drugs often require continuous dosing over a certain period, so drug prices and patients' out-of-pocket costs can influence actual prescription expansion. For epeleglenatide as well, translating the competitiveness secured in clinical trials into commercial success is expected to hinge on pricing policy and market accessibility.

It is also worth considering that in the domestic obesity treatment market, the drug must compete with products from global pharmaceutical companies. Price competitiveness compared to existing treatments, physicians' prescription choices, and patients' treatment persistence can all influence the market expansion process.

However, the actual selling price and market share are matters that will be finalized through future approval and launch processes, making it difficult to conclude commercial success at the current stage. Hanmi Pharmaceutical's mid- to long-term corporate value also needs to be assessed comprehensively, considering epeleglenatide's development results, commercialization strategy, and the performance trends of its existing pharmaceutical business.

With Hanmi Pharmaceutical rising to 373,000 won, the market is watching how the price competitiveness of its obesity treatment and future launch strategy will affect the company's value.

[This article is provided for informational purposes to aid investment decisions and does not recommend buying or selling any specific stock. Circumstances may vary depending on market conditions. Investment decisions and any resulting responsibility rest with the investor. AI provided some assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.